Press Releases

Date Title and Summary
Toggle Summary New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat
Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications MADISON, Wis. , Dec. 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an international retrospective multicenter
Toggle Summary Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
MADISON, Wis. , Nov. 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Mike Murphy , the company's new Vice President, Corporate Controller. As a material inducement to Mr.
Toggle Summary Accuray Reports Fiscal 2025 First Quarter Financial Results
Strong Start to Fiscal Year, Raises 2025 Guidance MADISON, Wis. , Nov. 6, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2024 .     "We continue to make solid progress in the execution of our strategic growth
Toggle Summary Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024
MADISON, Wis. , Oct. 23, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2025, ended September 30, 2024 , during a conference call hosted by company management at 1:30 p.m. PT / 4:30 p.m. ET on November 6, 2024 .
Toggle Summary Accuray Appoints Michael Murphy as VP, Corporate Controller
MADISON, Wis. , Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Michael Murphy , CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory
Toggle Summary New England Journal of Medicine Study Reaffirms Five Session Radiation Treatment Provides Comparable Rates of Cancer Control, Tolerability and Sexual Functioning to Conventional Radiotherapy Treatment in Men with Localized Prostate Cancer
The Precision of Stereotactic Body Radiation Therapy (SBRT), an Advanced Treatment Technique, Enables Treatment in Five Days, Significantly Reducing the Time Men Must Spend Undergoing Care MADISON, Wis. , Oct. 17, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that results
Toggle Summary Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence
MADISON, Wis. , Oct. 15, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced that, effective as of today, Suzanne Winter has returned from her temporary medical leave and assumed her full duties as President and Chief Executive Officer.
Toggle Summary Accuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife® S7™ System Medical Professional Training
Accuray is the first industry partner to open a facility at the Genolier Innovation Hub, created to provide opportunities for clinician-industry collaborations that can help accelerate improvements in patient care New Accuray CyberComm™ tool was used to significantly reduce the CyberKnife ®  S7™
Toggle Summary Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution
The Technology Will Play an Important Role in the Hospital's Plan to Expand Patient Access to High Precision Radiation Therapy Treatments MADISON, Wis. , Sept. 10, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Gifu Prefectural General Medical Center is setting a new
Toggle Summary Accuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence
MADISON, Wis. , Sept. 3, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that President and Chief Executive Officer Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately.

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.